Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, novembre 18
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Crescent Biopharma Inc
CBIO
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$13.04
-0.46
-3.41%
À la clôture: Nov 17, 4:00 PM EST
$13.50
0.46
3.53%
Après les heures: 8:34 AM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Crescent Biopharma Financials
Crescent Biopharma (CBIO) financial statements — income, revenue, gross margin and key metrics.
Résultats:
Les résultats Q3 2026 ont été publiés le jeu. nov. 12th, après la fermeture du marché
Earnings & Guidance News
PRO
Crescent Biopharma Q3 EPS $(0.90) Misses $(0.72) Estimate, Sales $3.117M Beat $312.500K Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.72) by 25 percent. This is a 29.13 percent increase over losses of $(1.27) per share
Benzinga Newsdesk
PRO
Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.79) by 6.33 percent. This is a 84.99 percent increase over losses of $(4.93) per share
Benzinga Newsdesk
PRO
Crescent Biopharma Q1 EPS $(0.70) Beats $(0.98) Estimate, Sales $1.039M Beat $357.143K Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.98) by 28.57 percent. This is a 96.43 percent increase over losses of $(19.63) per share
Benzinga Newsdesk
PRO
Crescent Biopharma Q4 EPS $(4.01) Misses $(2.31) Estimate, Sales $10.844M Beat $4.000M Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(4.01) per share which missed the analyst consensus estimate of $(2.31) by 73.44 percent. This is a 79.69 percent increase over losses of $(19.74) per share
Benzinga Newsdesk
PRO
Crescent Biopharma Q3 EPS $(1.27) Beats $(1.98) Estimate
Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.98) by 35.92 percent.
Benzinga Newsdesk
PRO
Crescent Biopharma Q2 EPS $(4.93) Misses $(1.11) Estimate, Cash Balance Of $152.6M
Benzinga Newsdesk